nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RPS6KA6—embryo—colon cancer	0.00608	0.0178	CbGeAlD
Ruxolitinib—BMPR2—blood vessel—colon cancer	0.00546	0.016	CbGeAlD
Ruxolitinib—PRKG2—smooth muscle tissue—colon cancer	0.00533	0.0156	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—colon cancer	0.00523	0.423	CbGdCrCtD
Ruxolitinib—PRKG2—renal system—colon cancer	0.00513	0.0151	CbGeAlD
Ruxolitinib—PLK3—embryo—colon cancer	0.00508	0.0149	CbGeAlD
Ruxolitinib—Myelosuppression—Vincristine—colon cancer	0.00476	0.0532	CcSEcCtD
Ruxolitinib—Myelosuppression—Fluorouracil—colon cancer	0.00444	0.0496	CcSEcCtD
Ruxolitinib—PRKG2—digestive system—colon cancer	0.00421	0.0123	CbGeAlD
Ruxolitinib—JAK2—blood vessel—colon cancer	0.00393	0.0115	CbGeAlD
Ruxolitinib—JAK1—embryo—colon cancer	0.0039	0.0114	CbGeAlD
Ruxolitinib—DCLK1—embryo—colon cancer	0.0039	0.0114	CbGeAlD
Ruxolitinib—PLK1—lymphoid tissue—colon cancer	0.00382	0.0112	CbGeAlD
Ruxolitinib—PLK1—digestive system—colon cancer	0.00378	0.0111	CbGeAlD
Ruxolitinib—PLK4—Topotecan—Irinotecan—colon cancer	0.00358	0.289	CbGdCrCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—colon cancer	0.00358	0.289	CbGdCrCtD
Ruxolitinib—ROCK1—embryo—colon cancer	0.00335	0.00984	CbGeAlD
Ruxolitinib—JAK1—epithelium—colon cancer	0.00318	0.00932	CbGeAlD
Ruxolitinib—DCLK3—vagina—colon cancer	0.00316	0.00927	CbGeAlD
Ruxolitinib—PRKG2—liver—colon cancer	0.00314	0.0092	CbGeAlD
Ruxolitinib—JAK1—smooth muscle tissue—colon cancer	0.00306	0.00898	CbGeAlD
Ruxolitinib—JAK1—renal system—colon cancer	0.00295	0.00865	CbGeAlD
Ruxolitinib—PRKCE—liver—colon cancer	0.00293	0.00859	CbGeAlD
Ruxolitinib—MARK2—digestive system—colon cancer	0.00286	0.00839	CbGeAlD
Ruxolitinib—RPS6KA6—liver—colon cancer	0.00281	0.00825	CbGeAlD
Ruxolitinib—PLK1—liver—colon cancer	0.00281	0.00825	CbGeAlD
Ruxolitinib—PLK3—vagina—colon cancer	0.00278	0.00816	CbGeAlD
Ruxolitinib—HIPK2—renal system—colon cancer	0.00275	0.00807	CbGeAlD
Ruxolitinib—DAPK3—smooth muscle tissue—colon cancer	0.00275	0.00806	CbGeAlD
Ruxolitinib—ROCK1—epithelium—colon cancer	0.00274	0.00803	CbGeAlD
Ruxolitinib—Night sweats—Capecitabine—colon cancer	0.0027	0.0301	CcSEcCtD
Ruxolitinib—DAPK3—renal system—colon cancer	0.00264	0.00775	CbGeAlD
Ruxolitinib—ROCK1—smooth muscle tissue—colon cancer	0.00264	0.00773	CbGeAlD
Ruxolitinib—CLK2—renal system—colon cancer	0.00262	0.00768	CbGeAlD
Ruxolitinib—CAMK1—vagina—colon cancer	0.0026	0.00763	CbGeAlD
Ruxolitinib—BMPR2—smooth muscle tissue—colon cancer	0.00256	0.00751	CbGeAlD
Ruxolitinib—ROCK1—renal system—colon cancer	0.00254	0.00744	CbGeAlD
Ruxolitinib—RET—embryo—colon cancer	0.00248	0.00727	CbGeAlD
Ruxolitinib—DYRK1A—renal system—colon cancer	0.00248	0.00726	CbGeAlD
Ruxolitinib—BMPR2—renal system—colon cancer	0.00247	0.00723	CbGeAlD
Ruxolitinib—JAK3—lymphoid tissue—colon cancer	0.00246	0.00722	CbGeAlD
Ruxolitinib—JAK1—lymphoid tissue—colon cancer	0.00245	0.00718	CbGeAlD
Ruxolitinib—JAK3—digestive system—colon cancer	0.00243	0.00714	CbGeAlD
Ruxolitinib—PLK4—lymphoid tissue—colon cancer	0.00243	0.00713	CbGeAlD
Ruxolitinib—JAK1—digestive system—colon cancer	0.00242	0.00709	CbGeAlD
Ruxolitinib—DCLK1—digestive system—colon cancer	0.00242	0.00709	CbGeAlD
Ruxolitinib—PLK3—liver—colon cancer	0.00235	0.00689	CbGeAlD
Ruxolitinib—JAK2—embryo—colon cancer	0.00234	0.00687	CbGeAlD
Ruxolitinib—TAOK2—vagina—colon cancer	0.00234	0.00686	CbGeAlD
Ruxolitinib—Bone pain—Vincristine—colon cancer	0.00233	0.0261	CcSEcCtD
Ruxolitinib—STK16—lymphoid tissue—colon cancer	0.0023	0.00674	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—colon cancer	0.00229	0.0067	CbGeAlD
Ruxolitinib—STK16—digestive system—colon cancer	0.00227	0.00666	CbGeAlD
Ruxolitinib—HIPK2—digestive system—colon cancer	0.00226	0.00662	CbGeAlD
Ruxolitinib—PRKCE—lymph node—colon cancer	0.00225	0.00658	CbGeAlD
Ruxolitinib—JAK1—bone marrow—colon cancer	0.00223	0.00654	CbGeAlD
Ruxolitinib—PLK4—bone marrow—colon cancer	0.00222	0.0065	CbGeAlD
Ruxolitinib—CAMK1—liver—colon cancer	0.0022	0.00644	CbGeAlD
Ruxolitinib—LRRK2—renal system—colon cancer	0.00219	0.00641	CbGeAlD
Ruxolitinib—CLK2—lymphoid tissue—colon cancer	0.00218	0.00638	CbGeAlD
Ruxolitinib—PLK1—lymph node—colon cancer	0.00216	0.00633	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—colon cancer	0.00216	0.00633	CbGeAlD
Ruxolitinib—JAK1—vagina—colon cancer	0.00214	0.00626	CbGeAlD
Ruxolitinib—DCLK1—vagina—colon cancer	0.00214	0.00626	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—colon cancer	0.00213	0.00624	CbGeAlD
Ruxolitinib—ROCK1—lymphoid tissue—colon cancer	0.00211	0.00618	CbGeAlD
Ruxolitinib—CAMK1D—vagina—colon cancer	0.00208	0.00611	CbGeAlD
Ruxolitinib—ROCK1—digestive system—colon cancer	0.00208	0.00611	CbGeAlD
Ruxolitinib—MKNK2—epithelium—colon cancer	0.00207	0.00608	CbGeAlD
Ruxolitinib—MAP3K7—smooth muscle tissue—colon cancer	0.00206	0.00605	CbGeAlD
Ruxolitinib—DYRK1A—lymphoid tissue—colon cancer	0.00206	0.00603	CbGeAlD
Ruxolitinib—BMPR2—lymphoid tissue—colon cancer	0.00205	0.00601	CbGeAlD
Ruxolitinib—DAPK2—vagina—colon cancer	0.00204	0.00597	CbGeAlD
Ruxolitinib—TYK2—smooth muscle tissue—colon cancer	0.00203	0.00594	CbGeAlD
Ruxolitinib—RET—epithelium—colon cancer	0.00202	0.00593	CbGeAlD
Ruxolitinib—BMPR2—digestive system—colon cancer	0.00202	0.00593	CbGeAlD
Ruxolitinib—STK16—vagina—colon cancer	0.002	0.00588	CbGeAlD
Ruxolitinib—MKNK2—smooth muscle tissue—colon cancer	0.002	0.00586	CbGeAlD
Ruxolitinib—IRAK1—smooth muscle tissue—colon cancer	0.002	0.00586	CbGeAlD
Ruxolitinib—CLK2—bone marrow—colon cancer	0.00198	0.00581	CbGeAlD
Ruxolitinib—TAOK2—liver—colon cancer	0.00197	0.00578	CbGeAlD
Ruxolitinib—TYK2—renal system—colon cancer	0.00195	0.00572	CbGeAlD
Ruxolitinib—Herpes zoster—Capecitabine—colon cancer	0.00193	0.0216	CcSEcCtD
Ruxolitinib—MKNK2—renal system—colon cancer	0.00192	0.00564	CbGeAlD
Ruxolitinib—DAPK3—vagina—colon cancer	0.00192	0.00562	CbGeAlD
Ruxolitinib—JAK2—epithelium—colon cancer	0.00191	0.00561	CbGeAlD
Ruxolitinib—CLK2—vagina—colon cancer	0.0019	0.00556	CbGeAlD
Ruxolitinib—RET—renal system—colon cancer	0.00188	0.0055	CbGeAlD
Ruxolitinib—JAK2—smooth muscle tissue—colon cancer	0.00184	0.0054	CbGeAlD
Ruxolitinib—CAMK2G—digestive system—colon cancer	0.00181	0.00531	CbGeAlD
Ruxolitinib—JAK1—liver—colon cancer	0.0018	0.00528	CbGeAlD
Ruxolitinib—PLK3—lymph node—colon cancer	0.0018	0.00528	CbGeAlD
Ruxolitinib—BMPR2—vagina—colon cancer	0.00179	0.00524	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—colon cancer	0.00178	0.00523	CbGeAlD
Ruxolitinib—JAK2—renal system—colon cancer	0.00177	0.0052	CbGeAlD
Ruxolitinib—CAMK1D—liver—colon cancer	0.00176	0.00516	CbGeAlD
Ruxolitinib—PHKG2—liver—colon cancer	0.00175	0.00513	CbGeAlD
Ruxolitinib—LTK—lymph node—colon cancer	0.00174	0.0051	CbGeAlD
Ruxolitinib—NUAK2—vagina—colon cancer	0.00171	0.00501	CbGeAlD
Ruxolitinib—STK16—liver—colon cancer	0.00169	0.00496	CbGeAlD
Ruxolitinib—CAMK1—lymph node—colon cancer	0.00168	0.00494	CbGeAlD
Ruxolitinib—HIPK2—liver—colon cancer	0.00168	0.00493	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—colon cancer	0.00167	0.00489	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—colon cancer	0.00167	0.00489	CbGeAlD
Ruxolitinib—Contusion—Capecitabine—colon cancer	0.00167	0.0186	CcSEcCtD
Ruxolitinib—MAP3K2—lymphoid tissue—colon cancer	0.00166	0.00488	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—colon cancer	0.00165	0.00485	CbGeAlD
Ruxolitinib—MARK2—lymph node—colon cancer	0.00163	0.00479	CbGeAlD
Ruxolitinib—TYK2—lymphoid tissue—colon cancer	0.00162	0.00475	CbGeAlD
Ruxolitinib—DAPK3—liver—colon cancer	0.00162	0.00474	CbGeAlD
Ruxolitinib—CLK2—liver—colon cancer	0.0016	0.00469	CbGeAlD
Ruxolitinib—TYK2—digestive system—colon cancer	0.0016	0.00469	CbGeAlD
Ruxolitinib—BMP2K—vagina—colon cancer	0.0016	0.00469	CbGeAlD
Ruxolitinib—CAMK2G—vagina—colon cancer	0.0016	0.00469	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—colon cancer	0.0016	0.00468	CbGeAlD
Ruxolitinib—LRRK2—vagina—colon cancer	0.00158	0.00465	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Irinotecan—colon cancer	0.00158	0.0176	CcSEcCtD
Ruxolitinib—MKNK2—digestive system—colon cancer	0.00158	0.00463	CbGeAlD
Ruxolitinib—TAOK3—renal system—colon cancer	0.00156	0.00457	CbGeAlD
Ruxolitinib—RET—lymphoid tissue—colon cancer	0.00156	0.00457	CbGeAlD
Ruxolitinib—ROCK1—liver—colon cancer	0.00155	0.00455	CbGeAlD
Ruxolitinib—RET—digestive system—colon cancer	0.00154	0.00451	CbGeAlD
Ruxolitinib—Bone pain—Capecitabine—colon cancer	0.00152	0.017	CcSEcCtD
Ruxolitinib—MAP3K2—bone marrow—colon cancer	0.00152	0.00444	CbGeAlD
Ruxolitinib—DYRK1A—liver—colon cancer	0.00151	0.00444	CbGeAlD
Ruxolitinib—TAOK2—lymph node—colon cancer	0.00151	0.00444	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Fluorouracil—colon cancer	0.00151	0.0169	CcSEcCtD
Ruxolitinib—BMPR2—liver—colon cancer	0.00151	0.00442	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—colon cancer	0.0015	0.0044	CbGeAlD
Ruxolitinib—TYK2—bone marrow—colon cancer	0.00147	0.00432	CbGeAlD
Ruxolitinib—JAK2—lymphoid tissue—colon cancer	0.00147	0.00432	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—colon cancer	0.00145	0.00427	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—colon cancer	0.00145	0.00427	CbGeAlD
Ruxolitinib—JAK2—digestive system—colon cancer	0.00145	0.00427	CbGeAlD
Ruxolitinib—NUAK2—liver—colon cancer	0.00144	0.00422	CbGeAlD
Ruxolitinib—Herpes zoster—Methotrexate—colon cancer	0.00144	0.0161	CcSEcCtD
Ruxolitinib—MAP3K7—vagina—colon cancer	0.00144	0.00422	CbGeAlD
Ruxolitinib—TYK2—vagina—colon cancer	0.00141	0.00414	CbGeAlD
Ruxolitinib—MKNK2—vagina—colon cancer	0.00139	0.00409	CbGeAlD
Ruxolitinib—JAK3—lymph node—colon cancer	0.00139	0.00408	CbGeAlD
Ruxolitinib—JAK1—lymph node—colon cancer	0.00138	0.00405	CbGeAlD
Ruxolitinib—DCLK1—lymph node—colon cancer	0.00138	0.00405	CbGeAlD
Ruxolitinib—PLK4—lymph node—colon cancer	0.00137	0.00403	CbGeAlD
Ruxolitinib—CAMK2G—liver—colon cancer	0.00135	0.00395	CbGeAlD
Ruxolitinib—BMP2K—liver—colon cancer	0.00135	0.00395	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—colon cancer	0.00135	0.00395	CbGeAlD
Ruxolitinib—JAK2—bone marrow—colon cancer	0.00134	0.00393	CbGeAlD
Ruxolitinib—PHKG2—lymph node—colon cancer	0.00134	0.00393	CbGeAlD
Ruxolitinib—LRRK2—liver—colon cancer	0.00134	0.00392	CbGeAlD
Ruxolitinib—Pancytopenia—Vincristine—colon cancer	0.00133	0.0149	CcSEcCtD
Ruxolitinib—DAPK2—lymph node—colon cancer	0.00132	0.00386	CbGeAlD
Ruxolitinib—Neutropenia—Vincristine—colon cancer	0.00131	0.0146	CcSEcCtD
Ruxolitinib—STK16—lymph node—colon cancer	0.0013	0.0038	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—colon cancer	0.00129	0.00379	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—colon cancer	0.00129	0.00379	CbGeAlD
Ruxolitinib—HIPK2—lymph node—colon cancer	0.00129	0.00378	CbGeAlD
Ruxolitinib—JAK2—vagina—colon cancer	0.00128	0.00377	CbGeAlD
Ruxolitinib—TAOK3—digestive system—colon cancer	0.00128	0.00375	CbGeAlD
Ruxolitinib—Neutropenia—Irinotecan—colon cancer	0.00128	0.0143	CcSEcCtD
Ruxolitinib—Weight decreased—Vincristine—colon cancer	0.00127	0.0142	CcSEcCtD
Ruxolitinib—Pancytopenia—Fluorouracil—colon cancer	0.00124	0.0139	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—colon cancer	0.00124	0.00363	CbGeAlD
Ruxolitinib—MAP3K3—vagina—colon cancer	0.00124	0.00363	CbGeAlD
Ruxolitinib—Weight decreased—Irinotecan—colon cancer	0.00123	0.0138	CcSEcCtD
Ruxolitinib—CLK2—lymph node—colon cancer	0.00123	0.0036	CbGeAlD
Ruxolitinib—MAP3K2—liver—colon cancer	0.00122	0.00359	CbGeAlD
Ruxolitinib—MAP3K7—liver—colon cancer	0.00121	0.00356	CbGeAlD
Ruxolitinib—TYK2—liver—colon cancer	0.00119	0.00349	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—colon cancer	0.00118	0.00346	CbGeAlD
Ruxolitinib—MKNK2—liver—colon cancer	0.00118	0.00345	CbGeAlD
Ruxolitinib—IRAK1—liver—colon cancer	0.00118	0.00345	CbGeAlD
Ruxolitinib—Infestation—Fluorouracil—colon cancer	0.00117	0.013	CcSEcCtD
Ruxolitinib—Infestation NOS—Fluorouracil—colon cancer	0.00117	0.013	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—colon cancer	0.00116	0.0034	CbGeAlD
Ruxolitinib—BMPR2—lymph node—colon cancer	0.00116	0.00339	CbGeAlD
Ruxolitinib—Urinary tract infection—Fluorouracil—colon cancer	0.00113	0.0127	CcSEcCtD
Ruxolitinib—TAOK3—vagina—colon cancer	0.00113	0.00331	CbGeAlD
Ruxolitinib—NUAK2—lymph node—colon cancer	0.0011	0.00324	CbGeAlD
Ruxolitinib—Epistaxis—Fluorouracil—colon cancer	0.0011	0.0123	CcSEcCtD
Ruxolitinib—Haemoglobin—Irinotecan—colon cancer	0.0011	0.0123	CcSEcCtD
Ruxolitinib—Haemorrhage—Irinotecan—colon cancer	0.00109	0.0122	CcSEcCtD
Ruxolitinib—JAK2—liver—colon cancer	0.00108	0.00318	CbGeAlD
Ruxolitinib—Gastrointestinal haemorrhage—Capecitabine—colon cancer	0.00106	0.0118	CcSEcCtD
Ruxolitinib—Haemoglobin—Fluorouracil—colon cancer	0.00105	0.0118	CcSEcCtD
Ruxolitinib—Haemorrhage—Fluorouracil—colon cancer	0.00105	0.0117	CcSEcCtD
Ruxolitinib—MAP3K3—liver—colon cancer	0.00104	0.00306	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—colon cancer	0.00103	0.00303	CbGeAlD
Ruxolitinib—BMP2K—lymph node—colon cancer	0.00103	0.00303	CbGeAlD
Ruxolitinib—LRRK2—lymph node—colon cancer	0.00102	0.003	CbGeAlD
Ruxolitinib—TAOK3—liver—colon cancer	0.000952	0.00279	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—colon cancer	0.000939	0.00275	CbGeAlD
Ruxolitinib—Flatulence—Irinotecan—colon cancer	0.000937	0.0105	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.000932	0.0104	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—colon cancer	0.00093	0.00273	CbGeAlD
Ruxolitinib—TYK2—lymph node—colon cancer	0.000913	0.00268	CbGeAlD
Ruxolitinib—Anaemia—Vincristine—colon cancer	0.000902	0.0101	CcSEcCtD
Ruxolitinib—IRAK1—lymph node—colon cancer	0.000901	0.00264	CbGeAlD
Ruxolitinib—MKNK2—lymph node—colon cancer	0.000901	0.00264	CbGeAlD
Ruxolitinib—RET—lymph node—colon cancer	0.000879	0.00258	CbGeAlD
Ruxolitinib—Anaemia—Irinotecan—colon cancer	0.000879	0.00982	CcSEcCtD
Ruxolitinib—Pancytopenia—Capecitabine—colon cancer	0.000867	0.00969	CcSEcCtD
Ruxolitinib—Neutropenia—Capecitabine—colon cancer	0.000854	0.00954	CcSEcCtD
Ruxolitinib—Anaemia—Fluorouracil—colon cancer	0.000842	0.00941	CcSEcCtD
Ruxolitinib—Weight increased—Capecitabine—colon cancer	0.000831	0.00929	CcSEcCtD
Ruxolitinib—JAK2—lymph node—colon cancer	0.000831	0.00244	CbGeAlD
Ruxolitinib—Weight decreased—Capecitabine—colon cancer	0.000826	0.00923	CcSEcCtD
Ruxolitinib—Infestation NOS—Capecitabine—colon cancer	0.000814	0.0091	CcSEcCtD
Ruxolitinib—Infestation—Capecitabine—colon cancer	0.000814	0.0091	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—colon cancer	0.000801	0.00235	CbGeAlD
Ruxolitinib—Infection—Vincristine—colon cancer	0.000792	0.00885	CcSEcCtD
Ruxolitinib—Urinary tract infection—Capecitabine—colon cancer	0.000792	0.00885	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vincristine—colon cancer	0.000781	0.00873	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vincristine—colon cancer	0.00078	0.00872	CcSEcCtD
Ruxolitinib—Haematuria—Capecitabine—colon cancer	0.000777	0.00868	CcSEcCtD
Ruxolitinib—Infection—Irinotecan—colon cancer	0.000771	0.00862	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Capecitabine—colon cancer	0.00077	0.00861	CcSEcCtD
Ruxolitinib—Epistaxis—Capecitabine—colon cancer	0.000768	0.00858	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—colon cancer	0.000761	0.0085	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—colon cancer	0.00076	0.00849	CcSEcCtD
Ruxolitinib—Infection—Fluorouracil—colon cancer	0.000738	0.00825	CcSEcCtD
Ruxolitinib—Haemoglobin—Capecitabine—colon cancer	0.000735	0.00821	CcSEcCtD
Ruxolitinib—Haemorrhage—Capecitabine—colon cancer	0.000731	0.00817	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—colon cancer	0.00073	0.00214	CbGeAlD
Ruxolitinib—Nervous system disorder—Fluorouracil—colon cancer	0.000729	0.00815	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000728	0.00813	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vincristine—colon cancer	0.000688	0.00769	CcSEcCtD
Ruxolitinib—Fatigue—Vincristine—colon cancer	0.000687	0.00768	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.00067	0.00749	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—colon cancer	0.000669	0.00748	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—colon cancer	0.000646	0.00722	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000642	0.00717	CcSEcCtD
Ruxolitinib—Malnutrition—Capecitabine—colon cancer	0.000636	0.00711	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—colon cancer	0.000636	0.0071	CcSEcCtD
Ruxolitinib—Body temperature increased—Vincristine—colon cancer	0.00063	0.00704	CcSEcCtD
Ruxolitinib—Flatulence—Capecitabine—colon cancer	0.000627	0.00701	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—colon cancer	0.000613	0.00686	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—colon cancer	0.000606	0.00677	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—colon cancer	0.000606	0.00677	CcSEcCtD
Ruxolitinib—Anaemia—Capecitabine—colon cancer	0.000588	0.00657	CcSEcCtD
Ruxolitinib—Body temperature increased—Fluorouracil—colon cancer	0.000588	0.00657	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—colon cancer	0.000578	0.00646	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—colon cancer	0.000573	0.00641	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—colon cancer	0.000572	0.00639	CcSEcCtD
Ruxolitinib—Asthenia—Vincristine—colon cancer	0.000572	0.00639	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—colon cancer	0.000557	0.00622	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—colon cancer	0.000547	0.00611	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—colon cancer	0.000544	0.00608	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000538	0.00601	CcSEcCtD
Ruxolitinib—Dizziness—Vincristine—colon cancer	0.000527	0.00589	CcSEcCtD
Ruxolitinib—Pruritus—Fluorouracil—colon cancer	0.000526	0.00588	CcSEcCtD
Ruxolitinib—Infection—Capecitabine—colon cancer	0.000516	0.00577	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—colon cancer	0.000513	0.00573	CcSEcCtD
Ruxolitinib—Nervous system disorder—Capecitabine—colon cancer	0.000509	0.00569	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Capecitabine—colon cancer	0.000509	0.00568	CcSEcCtD
Ruxolitinib—Skin disorder—Capecitabine—colon cancer	0.000505	0.00564	CcSEcCtD
Ruxolitinib—Headache—Vincristine—colon cancer	0.000499	0.00558	CcSEcCtD
Ruxolitinib—Dizziness—Fluorouracil—colon cancer	0.000492	0.00549	CcSEcCtD
Ruxolitinib—Headache—Irinotecan—colon cancer	0.000486	0.00543	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—colon cancer	0.000474	0.00529	CcSEcCtD
Ruxolitinib—CYP3A4—renal system—colon cancer	0.000473	0.00139	CbGeAlD
Ruxolitinib—Headache—Fluorouracil—colon cancer	0.000466	0.0052	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000448	0.00501	CcSEcCtD
Ruxolitinib—Fatigue—Capecitabine—colon cancer	0.000448	0.005	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—colon cancer	0.000438	0.00489	CcSEcCtD
Ruxolitinib—Body temperature increased—Capecitabine—colon cancer	0.000411	0.00459	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000401	0.00448	CcSEcCtD
Ruxolitinib—CYP3A4—digestive system—colon cancer	0.000388	0.00114	CbGeAlD
Ruxolitinib—Infection—Methotrexate—colon cancer	0.000384	0.00429	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—colon cancer	0.000379	0.00424	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—colon cancer	0.000379	0.00423	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—colon cancer	0.000376	0.0042	CcSEcCtD
Ruxolitinib—Asthenia—Capecitabine—colon cancer	0.000373	0.00416	CcSEcCtD
Ruxolitinib—Pruritus—Capecitabine—colon cancer	0.000367	0.00411	CcSEcCtD
Ruxolitinib—Dizziness—Capecitabine—colon cancer	0.000343	0.00384	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—colon cancer	0.000334	0.00373	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—colon cancer	0.000333	0.00373	CcSEcCtD
Ruxolitinib—Headache—Capecitabine—colon cancer	0.000325	0.00364	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—colon cancer	0.000306	0.00342	CcSEcCtD
Ruxolitinib—CYP3A4—liver—colon cancer	0.000289	0.000848	CbGeAlD
Ruxolitinib—Asthenia—Methotrexate—colon cancer	0.000277	0.0031	CcSEcCtD
Ruxolitinib—Pruritus—Methotrexate—colon cancer	0.000274	0.00306	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—colon cancer	0.000256	0.00286	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—colon cancer	0.000242	0.00271	CcSEcCtD
Ruxolitinib—JAK1—Disease—MYC—colon cancer	1.62e-05	2.91e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—colon cancer	1.62e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDKN1A—colon cancer	1.61e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGFR3—colon cancer	1.61e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—PIK3CA—colon cancer	1.6e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—colon cancer	1.6e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—colon cancer	1.6e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDKN1A—colon cancer	1.59e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—PIK3CA—colon cancer	1.59e-05	2.86e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—colon cancer	1.59e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—colon cancer	1.59e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APC—colon cancer	1.57e-05	2.82e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MYC—colon cancer	1.56e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDKN1A—colon cancer	1.56e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—colon cancer	1.56e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—colon cancer	1.56e-05	2.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—colon cancer	1.55e-05	2.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—colon cancer	1.55e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—colon cancer	1.55e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—colon cancer	1.55e-05	2.78e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—colon cancer	1.54e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—colon cancer	1.54e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—colon cancer	1.54e-05	2.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EP300—colon cancer	1.53e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—colon cancer	1.53e-05	2.75e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APC—colon cancer	1.52e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—colon cancer	1.52e-05	2.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDKN1A—colon cancer	1.52e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EP300—colon cancer	1.51e-05	2.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—colon cancer	1.51e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—colon cancer	1.5e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—colon cancer	1.5e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—colon cancer	1.5e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—colon cancer	1.5e-05	2.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—PIK3CA—colon cancer	1.49e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—SRC—colon cancer	1.49e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EP300—colon cancer	1.49e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—colon cancer	1.48e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—colon cancer	1.48e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APC—colon cancer	1.48e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—colon cancer	1.47e-05	2.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SRC—colon cancer	1.47e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—colon cancer	1.47e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—colon cancer	1.47e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—colon cancer	1.45e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—SRC—colon cancer	1.45e-05	2.6e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—colon cancer	1.45e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—colon cancer	1.44e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDKN1A—colon cancer	1.44e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EP300—colon cancer	1.44e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—colon cancer	1.44e-05	2.58e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—colon cancer	1.43e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—colon cancer	1.43e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—colon cancer	1.43e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—colon cancer	1.43e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—colon cancer	1.43e-05	2.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—colon cancer	1.42e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—colon cancer	1.42e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—colon cancer	1.42e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—SRC—colon cancer	1.4e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—colon cancer	1.4e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—colon cancer	1.39e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—colon cancer	1.39e-05	2.5e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—colon cancer	1.39e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—colon cancer	1.39e-05	2.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—colon cancer	1.38e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—colon cancer	1.38e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—colon cancer	1.38e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EP300—colon cancer	1.37e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDKN1A—colon cancer	1.37e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—colon cancer	1.35e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDKN1A—colon cancer	1.35e-05	2.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SRC—colon cancer	1.34e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—colon cancer	1.33e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—colon cancer	1.33e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—colon cancer	1.32e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—colon cancer	1.32e-05	2.38e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MYC—colon cancer	1.32e-05	2.37e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—colon cancer	1.32e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—colon cancer	1.31e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—colon cancer	1.31e-05	2.35e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—colon cancer	1.31e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EP300—colon cancer	1.3e-05	2.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—colon cancer	1.3e-05	2.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—colon cancer	1.29e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—colon cancer	1.29e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—colon cancer	1.28e-05	2.31e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EP300—colon cancer	1.28e-05	2.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—colon cancer	1.27e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—colon cancer	1.27e-05	2.28e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SRC—colon cancer	1.27e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR3—colon cancer	1.26e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—colon cancer	1.25e-05	2.25e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SRC—colon cancer	1.25e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—colon cancer	1.23e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—colon cancer	1.23e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—colon cancer	1.23e-05	2.21e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—colon cancer	1.23e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—colon cancer	1.22e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—colon cancer	1.22e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—colon cancer	1.22e-05	2.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—colon cancer	1.21e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—colon cancer	1.21e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—colon cancer	1.2e-05	2.16e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—colon cancer	1.2e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—colon cancer	1.2e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—colon cancer	1.2e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—colon cancer	1.19e-05	2.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—colon cancer	1.18e-05	2.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—colon cancer	1.17e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—colon cancer	1.17e-05	2.1e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—colon cancer	1.16e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—colon cancer	1.15e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—colon cancer	1.15e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—colon cancer	1.14e-05	2.04e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—colon cancer	1.13e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—colon cancer	1.13e-05	2.03e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—colon cancer	1.13e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—colon cancer	1.12e-05	2.02e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—colon cancer	1.12e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—colon cancer	1.12e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—colon cancer	1.12e-05	2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—colon cancer	1.11e-05	2e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—colon cancer	1.11e-05	2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—colon cancer	1.11e-05	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—colon cancer	1.11e-05	1.99e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—colon cancer	1.11e-05	1.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—colon cancer	1.1e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—colon cancer	1.1e-05	1.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—colon cancer	1.09e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—colon cancer	1.09e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—colon cancer	1.09e-05	1.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—colon cancer	1.08e-05	1.95e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—colon cancer	1.08e-05	1.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—colon cancer	1.08e-05	1.93e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—colon cancer	1.07e-05	1.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—colon cancer	1.07e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—colon cancer	1.07e-05	1.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—colon cancer	1.05e-05	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—colon cancer	1.05e-05	1.89e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—colon cancer	1.05e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—colon cancer	1.05e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—colon cancer	1.04e-05	1.88e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—colon cancer	1.04e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—colon cancer	1.04e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—colon cancer	1.04e-05	1.87e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—colon cancer	1.04e-05	1.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—colon cancer	1.03e-05	1.86e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—colon cancer	1.03e-05	1.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—colon cancer	1.02e-05	1.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—colon cancer	1.02e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—colon cancer	1.01e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—colon cancer	1.01e-05	1.82e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—colon cancer	1.01e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—colon cancer	1.01e-05	1.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—colon cancer	1e-05	1.8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—colon cancer	9.94e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—colon cancer	9.91e-06	1.78e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—colon cancer	9.88e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—colon cancer	9.84e-06	1.77e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—colon cancer	9.8e-06	1.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—colon cancer	9.74e-06	1.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—colon cancer	9.64e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—colon cancer	9.64e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—colon cancer	9.62e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—colon cancer	9.61e-06	1.73e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—colon cancer	9.48e-06	1.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—colon cancer	9.4e-06	1.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—colon cancer	9.38e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—colon cancer	9.35e-06	1.68e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—colon cancer	9.33e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—colon cancer	9.32e-06	1.67e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—colon cancer	9.27e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—colon cancer	9.26e-06	1.66e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—colon cancer	9.17e-06	1.65e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—colon cancer	9.15e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—colon cancer	9.13e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—colon cancer	9.11e-06	1.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—colon cancer	9.08e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—colon cancer	9.07e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—colon cancer	9.07e-06	1.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—colon cancer	9.05e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—colon cancer	9e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—colon cancer	8.99e-06	1.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—colon cancer	8.92e-06	1.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—colon cancer	8.87e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—colon cancer	8.84e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—colon cancer	8.77e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—colon cancer	8.73e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—colon cancer	8.72e-06	1.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—colon cancer	8.63e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—colon cancer	8.61e-06	1.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—colon cancer	8.45e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—colon cancer	8.45e-06	1.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—colon cancer	8.38e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—colon cancer	8.38e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—colon cancer	8.36e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—colon cancer	8.34e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—colon cancer	8.3e-06	1.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—colon cancer	8.21e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—colon cancer	8.2e-06	1.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—colon cancer	8.14e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—colon cancer	8.13e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—colon cancer	8.11e-06	1.46e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—colon cancer	7.98e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—colon cancer	7.95e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—colon cancer	7.92e-06	1.42e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—colon cancer	7.87e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—colon cancer	7.84e-06	1.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—colon cancer	7.74e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—colon cancer	7.74e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—colon cancer	7.72e-06	1.39e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—colon cancer	7.7e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—colon cancer	7.66e-06	1.38e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—colon cancer	7.51e-06	1.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—colon cancer	7.46e-06	1.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—colon cancer	7.33e-06	1.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—colon cancer	7.29e-06	1.31e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—colon cancer	7.12e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—colon cancer	7.12e-06	1.28e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—colon cancer	7.09e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—colon cancer	7.09e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—colon cancer	6.9e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—colon cancer	6.9e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—colon cancer	6.88e-06	1.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—colon cancer	6.82e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—colon cancer	6.81e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—colon cancer	6.78e-06	1.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—colon cancer	6.68e-06	1.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—colon cancer	6.58e-06	1.18e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—colon cancer	6.39e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—colon cancer	6.35e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—colon cancer	6.34e-06	1.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—colon cancer	6.29e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—colon cancer	6.21e-06	1.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—colon cancer	5.99e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—colon cancer	5.87e-06	1.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—colon cancer	5.81e-06	1.04e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—colon cancer	5.64e-06	1.01e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—colon cancer	5.41e-06	9.72e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—colon cancer	5.39e-06	9.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—colon cancer	5.32e-06	9.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—colon cancer	5.22e-06	9.36e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—colon cancer	4.99e-06	8.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—colon cancer	4.41e-06	7.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—colon cancer	3.77e-06	6.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—colon cancer	2.96e-06	5.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—colon cancer	2.46e-06	4.42e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—colon cancer	1.82e-06	3.27e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—colon cancer	1.49e-06	2.67e-06	CbGpPWpGaD
